Cardiology Perspective

 
 

  • Apr 26 2024 This Week in Cardiology   A listener defends colored boxes in guidelines; mysteries of non-culprit coronary lesions during PCI, and of AF ablation; and surrogate markers are the topics John Mandrola, MD, covers in this week’s podcast.
  • Episode 3: Is Pulmonary Rehab Right for Your Patient With COPD?   Join Dr Leah Witt and nurse practitioner Chris Garvey as they discuss pulmonary rehab, an underutilized treatment for people living with COPD.
  • We've Come Full Circle in Managing CKM A recent statement provides guidance on managing cardiovascular-kidney-metabolic syndrome, bringing us back to the roots of treating metabolic syndrome, writes Naresh Kanumilli, MBBS.
  • Opportunistic AI for Medical Scans A remarkable wealth of data are being missed.
  • Drugs and Teeth: Prescription Meds With Dental Effects   The Curbsiders got an expert's answers to common questions about drugs and dental care.
  • Conscience Laws: Inform Patients Early of All Options   Ethicist Art Caplan discusses the rise of state conscience laws and doctors' obligation to inform patients of all options for receiving care.
  • Are Women Better Doctors Than Men?   Investigators took a unique approach to try to answer this age-old question in medicine.
  • Threshold for Transfusion in ACS: Still Room for Discretion   Cardiologists Michelle O’Donoghue and Sunil Rao discuss more details from the MINT trial on a liberal vs conservative approach to blood transfusion in patients with anemia and acute coronary syndrome.
  • How to Make the Most of Your Patient's Holter Monitor An electrophysiologist shares eight tips for making the best use of the data that this device provides.
  • Adding Life to Your Patients' Years Is it enough to just help adults live longer? Lifestyle medicine can add life instead of just years.
  • Apr 19 2024 This Week in Cardiology   ACC Part 2: The TACT2 trial of chelation, inter-atrial shunts for HF, and triglyceride lowering; plus diltiazem and Factor Xa anticoagulants are the topics John Mandrola, MD, covers this week.
  • Are Carbs Really the Enemy? Our diet hasn't necessarily adapted to the ready food supply, which has changed over the years. Caroline Apovian, MD, explains why we need carbs and which ones are best.
  • Infographic: Doctors' Pay and If They Think It's Enough Physicians reveal their compensation rose about 3% on average in 2023 and discuss whether the profession in general and they individually are adequately paid.
  • How Can Doctors Best Assess Worsening Dengue Cases? It is important to inform patients about warning signs such as abdominal pain, repeated vomiting, decreased urine output, or dizziness when standing, says an epidemiologist.
  • S2 Episode 5: Pulmonary Hypertension: Essential Insights for Cardiologists   Drs Michelle Kittleson and Ronald Oudiz dive into everything cardiologists need to know about the diagnosis and treatment of pulmonary hypertension.
  • Correlation Is Not Causation, Wink, Is Not Good Enough   Cardiology researchers Bob Harrington and Bobby Yeh discuss how to do better observational research and the controversial notion of making causal inferences from such data.
  • ACC 2024 Chelation Therapy and CV Risk: Why TACT2 Showed No Benefit   Tricia Ward interviews Gervasio Lamas TACT2, a trial of chelation therapy to lower CV risk presented at the 2024 ACC Scientific Sessions, and why its findings differed from those of TACT.
  • 'Difficult Patient': Stigmatizing Words and Medical Error   In a hospital study, the use of certain words and language patterns in the medical record was linked with diagnostic errors. Dr F Perry Wilson comments.
  • A Shot in the Arm for Uncontrolled Hypertension   Cardiologists Michelle O'Donoghue and Akshay Desai discuss the results of KARDIA-2 on the siRNA drug zilebesiran in patients with uncontrolled hypertension and the potential role of renal denervation.
  • ACC 2024: Insights on Advancements in Lipid Management   Dr Erin D. Michos highlights five trials presented at ACC that offer exciting advancements in lipid science.
  • Apr 12 2024 This Week in Cardiology   ACC Recap #1: DanGer Shock (plus a sobering JAMA research letter on Impella use), REDUCE-AMI, PREVENT, and EMPACT-MI are the topics John Mandrola, MD, covers in this week’s podcast.
  • EMPACT-MI: Another SGLT2 Inhibitor Miss Post-MI Empagliflozin added to standard care did not improve outcomes in post-MI patients at risk for heart failure. John Mandrola, MD, sees the diminishing returns for add-on drugs as positive for patients.
  • ACC 2024 Semaglutide Benefits in HFpEF Step Beyond Weight Loss   Drs Piña and Kosiborod discuss semaglutide in obesity-related HF with and without diabetes. Both STEP HFpEF trials show similar HF benefits despite less weight loss in patients with diabetes.
  • Identification and Management of MASLD: Primary Care Tips   Dr Kevin Fernando discusses the identification and management of people with MASLD in primary care.
  • Reduce Sitting Time to Lower Blood Pressure   Dr JoAnn Manson comments on the significance of a randomized trial showing the benefits of reduced sitting time in older adults.
  • ACC 2024 Preventive Coronary Stents: Not There Yet The PREVENT trial on stenting stable plaques deemed vulnerable by imaging criteria suggests a benefit over medical therapy alone. John Mandrola, MD, finds it provocative but not yet ready to act on.
  • Is Your EMS System Leading the Way in Emergency Care?   Join Drs Glatter and Pepe as they explore the intricacies of EMS care, revealing disparities and providing insights and solutions alongside Dr Weston.
  • Managing CKD in Primary Care: Latest Guidelines   An explosion of new treatments can stave off the need for dialysis in many patients with CKD.
  • ACC 2024 Beta-Blockers Post-MI Past Their Expiration Date: REDUCE-AMI REDUCE-AMI showed no benefit for routine beta-blockers post–MI in patients with normal ejection fraction. John Mandrola, MD, asks: Does evidence-based medicine need expiration dates?
  • ACC 2024 Impella Saves Lives in CS, but Patient Selection Key In the first randomized trial of Impella in a select group of patients with AMI and cardiogenic shock, the device saved lives. The high rate of serious adverse events calls us to pay attention to the nuances of the data, says John Mandrola, MD.
  • Post-ICU Syndrome: The Long Road to Recovery   Drs Robert Glatter and Nida Qadir discuss post–intensive care syndrome, including what it is, management opportunities, and funding needs for the future.
  • How to Keep Your Patients Safe This Ramadan With increasing prevalence of chronic illnesses, old age, and frailty, doctors are likely to encounter Muslim patients with chronic conditions asking for their advice.
  • ESC 2022 ESC 2022
  • ACC 2022 ACC 2022
  • AHA 2021 AHA 2021
  • BCS 2021 BCS 2021
  • ESC 2021 ESC 2021 Read clinically focused news coverage of key developments from ESC 2021
  • TCT 2020 TCT 2020
  • ESC 2020 ESC 2020